Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study

Senn, Christoph; Günther, Beatrice; Popp, Albrecht; Perrelet, Romain; Hans, D; Lippuner, Kurt (2014). Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study. Osteoporosis international, 25(7), pp. 1945-1951. Springer 10.1007/s00198-014-2703-8

[img] Text
art%3A10.1007%2Fs00198-014-2703-8.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (209kB) | Request a copy
[img]
Preview
Text
64213.pdf - Accepted Version
Available under License Publisher holds Copyright.

Download (2MB) | Preview

UNLABELLED Treatment effects over 2 years of teriparatide vs. ibandronate in postmenopausal women with osteoporosis were compared using lumbar spine bone mineral density (BMD) and trabecular bone score (TBS). Teriparatide induced larger increases in BMD and TBS compared to ibandronate, suggesting a more pronounced effect on bone microarchitecture of the bone anabolic drug. INTRODUCTION The trabecular bone score (TBS) is an index of bone microarchitecture, independent of bone mineral density (BMD), calculated from anteroposterior spine dual X-ray absorptiometry (DXA) scans. The potential role of TBS for monitoring treatment response with bone-active substances is not established. The aim of this study was to compare the effects of recombinant human 1-34 parathyroid hormone (teriparatide) and the bisphosphonate ibandronate (IBN), on lumbar spine (LS) BMD and TBS in postmenopausal women with osteoporosis. METHODS Two patient groups with matched age, body mass index (BMI), and baseline LS BMD, treated with either daily subcutaneous teriparatide (N = 65) or quarterly intravenous IBN (N = 122) during 2 years and with available LS BMD measurements at baseline and 2 years after treatment initiation were compared. RESULTS Baseline characteristics (overall mean ± SD) were similar between groups in terms of age 67.9 ± 7.4 years, body mass index 23.8 ± 3.8 kg/m(2), BMD L1-L4 0.741 ± 0.100 g/cm(2), and TBS 1.208 ± 0.100. Over 24 months, teriparatide induced a significantly larger increase in LS BMD and TBS than IBN (+7.6 % ± 6.3 vs. +2.9 % ± 3.3 and +4.3 % ± 6.6 vs. +0.3 % ± 4.1, respectively; P < 0.0001 for both). LS BMD and TBS were only weakly correlated at baseline (r (2) = 0.04) with no correlation between the changes in BMD and TBS over 24 months. CONCLUSIONS In postmenopausal women with osteoporosis, a 2-year treatment with teriparatide led to a significantly larger increase in LS BMD and TBS than IBN, suggesting that teriparatide had more pronounced effects on bone microarchitecture than IBN.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Orthopaedic, Plastic and Hand Surgery (DOPH) > Clinic of Osteoporosis

UniBE Contributor:

Senn, Christoph; Günther, Beatrice; Popp, Albrecht; Perrelet, Romain and Lippuner, Kurt

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0937-941X

Publisher:

Springer

Language:

English

Submitter:

Romain Perrelet

Date Deposited:

10 Mar 2015 13:47

Last Modified:

07 Dec 2015 13:34

Publisher DOI:

10.1007/s00198-014-2703-8

PubMed ID:

24760244

BORIS DOI:

10.7892/boris.64213

URI:

https://boris.unibe.ch/id/eprint/64213

Actions (login required)

Edit item Edit item
Provide Feedback